You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Last Updated: May 9, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR INLYTA

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Inlyta

Subscribe to access the full database, or Get Started for $10
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00700258	Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]	Recruiting	Pfizer	N/A	2013-01-01	The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel®, Sutent®, and/or Inlyta® therapies in patients with advanced renal cell carcinoma, recurrent / refractory mantle cell lymphoma (MCL) and gastro-intestinal stroma tumors (GIST) under the conditions of routine use
NCT01321437	Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma	Active, not recruiting	Pfizer	Phase 2	2011-12-01	The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma.
NCT01321437	Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma	Active, not recruiting	University of California, Irvine	Phase 2	2011-12-01	The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Inlyta

Condition Name

Chart
Table

Condition Name for Inlyta
Intervention	Trials
Clear Cell Renal Cell Carcinoma	5
Carcinoma, Renal Cell	3
Renal Cell Carcinoma	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Inlyta
Intervention	Trials
Carcinoma, Renal Cell	17
Carcinoma	15
Melanoma	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Inlyta

Trials by Country

Map
Table

Trials by Country for Inlyta
Location	Trials
United States	142
Japan	10
Canada	7
Russian Federation	6
Korea, Republic of	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Inlyta
Location	Trials
California	9
Texas	9
New York	7
Oregon	6
Florida	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Inlyta

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Inlyta
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	2
Phase 2	22
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Inlyta
Clinical Trial Phase	Trials
Recruiting	20
Not yet recruiting	13
Active, not recruiting	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Inlyta

Sponsor Name

Chart
Table

Sponsor Name for Inlyta
Sponsor	Trials
Pfizer	13
National Cancer Institute (NCI)	5
Merck Sharp & Dohme Corp.	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Inlyta
Sponsor	Trials
Industry	31
Other	28
NIH	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Mallinckrodt

AstraZeneca

Merck

McKinsey

Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.